Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

BACKGROUND: Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity. The objective of this study was to evaluate the efficacy and safety of ibrexafungerp co...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwebke, Jane R, Sobel, Ryan, Gersten, Janet K, Sussman, Steven A, Lederman, Samuel N, Jacobs, Mark A, Chappell, B Todd, Weinstein, David L, Moffett, Alfred H, Azie, Nkechi E, Angulo, David A, Harriott, Itzel A, Borroto-Esoda, Katyna, Ghannoum, Mahmoud A, Nyirjesy, Paul, Sobel, Jack D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187327/
https://www.ncbi.nlm.nih.gov/pubmed/34467969
http://dx.doi.org/10.1093/cid/ciab750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187327/
https://www.ncbi.nlm.nih.gov/pubmed/34467969
http://dx.doi.org/10.1093/cid/ciab750

Ejemplares similares